Using TTV virus to manage immune drugs in kidney transplant
Part of Cancer, Infections clinical trials.
This trial uses a virus called TTV to see if it can help doctors safely adjust immunosuppression drugs in kidney transplant patients. It aims to find a way to lower the risk of rejection while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You received a kidney transplant (up to your third one) 1 to 4 years ago
- Your kidney function has been stable over the last 6 months
- You are taking a CNI drug (like tacrolimus or cyclosporine) and MMF (like CellCept or Myfortic) with or without steroids
- You have a detectable TTV virus level in your blood
- You do not have certain donor-specific antibodies or BK virus in your blood
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This trial is testing a new blood test called T-ID that monitors your immune system after a kidney transplant. It may help doctors detect early signs of rejection so they can adjust your treatment before problems start.
This study looks at whether a virus called TTV (torque teno virus) in the blood can help predict how well immunotherapy works for advanced kidney cancer. If you have clear cell renal cell carcinoma that has spread and are about to start your first immunotherapy, you may be able to join.
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.